



Oru, E., Trickey, A., Shirali, R., Kanter, S., & Easterbrook, P. (2021). Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. *Lancet Global Health*, 9(4), e431-e445.
[https://doi.org/10.1016/S2214-109X\(20\)30505-2](https://doi.org/10.1016/S2214-109X(20)30505-2)

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1016/S2214-109X\(20\)30505-2](https://doi.org/10.1016/S2214-109X(20)30505-2)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(20\)30505-2/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30505-2/fulltext) . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis

Ena Oru, Adam Trickey, Rohan Shirali, Steve KanTERS, Philippa Easterbrook



Summary

Background Increasing access to hepatitis C virus (HCV) care and treatment will require simplified service delivery models. We aimed to evaluate the effects of decentralisation and integration of testing, care, and treatment with harm-reduction and other services, and task-shifting to non-specialists on outcomes across the HCV care continuum.

Methods For this systematic review and meta-analysis, we searched PubMed, Embase, WHO Global Index Medicus, and conference abstracts for studies published between Jan 1, 2008, and Feb 20, 2018, that evaluated uptake of HCV testing, linkage to care, treatment, cure assessment, and sustained virological response at 12 weeks (SVR12) in people who inject drugs, people in prisons, people living with HIV, and the general population. Randomised controlled trials, non-randomised studies, and observational studies were eligible for inclusion. Studies with a sample size of ten or less for the largest denominator were excluded. Studies were categorised according to the level of decentralisation: full (testing and treatment at same site), partial (testing at decentralised site and referral elsewhere for treatment), or none. Task-shifting was categorised as treatment by specialists or non-specialists. Data on outcomes across the HCV care continuum (linkage to care, treatment uptake, and SVR12) were pooled using random-effects meta-analysis.

Findings Our search identified 8050 reports, of which 132 met the eligibility criteria, and an additional ten reports were identified from reference citations and grey literature. Therefore, the final synthesis included 142 studies from 34 countries (20 [14%] studies from low-income and middle-income countries) and a total of 489 996 patients (239 446 [49%] from low-income and middle-income countries). Rates of linkage to care were higher with full decentralisation compared with partial or no decentralisation among people who inject drugs (full 72% [95% CI 57–85] vs partial 53% [38–67] vs none 47% [11–84]) and among people in prisons (full 94% [79–100] vs partial 50% [29–71]), although the CIs overlap for people who inject drugs. Similarly, treatment uptake was higher with full decentralisation compared with partial or no decentralisation (people who inject drugs: full 73% [65–80] vs partial 66% [55–77] vs none 35% [23–48]; people in prisons: full 72% [48–91] vs partial 39% [17–63]), although CIs overlap for full versus partial decentralisation. The results in the general population studies were more heterogeneous. SVR12 rates were high ($\geq 90\%$) across different levels of decentralisation in all populations. Task-shifting of care and treatment to a non-specialist was associated with similar SVR12 rates to treatment delivered by specialists. There was a severe or critical risk of bias for 46% of studies, and heterogeneity across studies tended to be very high ($I^2 > 90\%$).

Interpretation Decentralisation and integration of HCV care to harm-reduction sites or primary care showed some evidence of improved access to testing, linkage to care, and treatment, and task-shifting of care and treatment to non-specialists was associated with similarly high cure rates to care delivered by specialists, across a range of populations and settings. These findings provide support for the adoption of decentralisation and task-shifting to non-specialists in national HCV programmes.

Funding Unitaid.

Copyright © 2021 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.

Introduction

Hepatitis C virus (HCV) infection is a major cause of liver disease that leads to approximately 399 000 deaths annually.¹ An estimated 71 million people are chronically infected, with a disproportionately high burden in low-income and middle-income countries (LMICs). In

recognition of this major global public health burden, in 2016, WHO launched a Global Health Sector Strategy on Viral Hepatitis 2016–2021.² This strategy outlined a set of global targets and the scale-up of five key synergistic interventions for prevention, testing, and treatment to achieve the goal of eliminating viral

Lancet Glob Health 2021;

9: e431–45

Published Online

February 24, 2021

[https://doi.org/10.1016/](https://doi.org/10.1016/S2214-109X(20)30505-2)

[S2214-109X\(20\)30505-2](https://doi.org/10.1016/S2214-109X(20)30505-2)

See [Comment](#) page e375

Department of Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland (E Oru MD, Prof P Easterbrook MD);

Population Health Sciences, University of Bristol, Bristol, UK (A Trickey PhD); Precision Xtract, Boston, MA, USA (R Shirali MSc); School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (S KanTERS PhD)

Correspondence to:

Prof Philippa Easterbrook, Department of Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva 1211, Switzerland easterbrookp@who.int

Research in context

Evidence before this study

We searched PubMed, Embase, WHO Global Index Medicus, WHO International Clinical Trials Registry, and conference abstracts for studies of models of hepatitis C virus (HCV) care. The search included studies in all languages published from Jan 1, 2008, to Feb 20, 2018. The following search terms were used: "hepatitis C OR HCV" AND "delivery of health care" OR "delivery of health care, integrated" OR "model of care" OR "community care" OR "primary care". We identified eight systematic reviews that had examined different interventions aimed to increase uptake of HCV testing, linkage to care, and treatment. The studies in these systematic reviews were mostly from high-income countries, focused only on certain steps in the care cascade, and were predominantly among people who inject drugs. Many were also done before the introduction of direct-acting antivirals (DAAs) and had small sample sizes (<50 patients). Nonetheless, previous studies found evidence that strategies such as offering HCV testing and care within harm-reduction services and primary care clinics would improve uptake of care and treatment.

Added value of this study

To inform future WHO global recommendations on simplified service delivery for HCV care and treatment, we assessed the effects of a range of different service delivery approaches, specifically decentralisation and task-shifting, on all key outcomes along the cascade of HCV care in people who inject drugs, people in prisons, people living with HIV, and the general population. Outcomes evaluated included uptake of serological and nucleic acid testing, linkage to care, treatment, cure

assessment (ie, sustained virological response at 12 weeks after the end of treatment, SVR12), and cure rate. Overall, studies that provided fully decentralised care had similar cure rates (for both interferon-based and DAA-based regimens) to those achieved at tertiary centres, but also had increased linkage to care and treatment among people who inject drugs, at sites where HCV testing and treatment were also integrated with delivery of harm-reduction services. Among people in prisons, studies with fully decentralised care had higher rates of linkage to care than those with partially decentralised care. Our study also showed that in all populations studied, task-shifting of HCV care and treatment to non-specialists achieved similarly high SVR12 cure rates to care provided by specialists.

Implications of all the available evidence

To meet the global targets for elimination of HCV, access to testing and treatment needs to be scaled up substantially. Our findings provide new evidence that decentralisation of testing, care, and treatment to harm-reduction sites among people who inject drugs and within prisons improves linkage to care and treatment, as well as achieving high cure rates. We also found that care delivered by non-specialists has similar outcomes to that delivered by specialists. This finding has direct implications for countries where HCV care and treatment are currently restricted to certain tertiary-care facilities or provided only by specialists (eg, hepatologists). Our results provide support for countries to expand access to their services for HCV testing, care, and treatment beyond specialist centres and providers to lower-level health facilities and to use the existing non-specialist and primary health-care workforce.

hepatitis as a public health threat by 2030 (ie, a reduction in hepatitis-related mortality by 65% and in incidence of chronic infections by 90%). Good progress has been made in several key LMICs, such as Egypt, Georgia, Rwanda, and Mongolia, in the scale-up of treatment access and highly effective preventive approaches to reduce transmission, such as blood and injection safety.³ However, we are far from achieving the 2030 coverage targets of 90% diagnosis and 80% treatment of those infected. As of 2017, only 20% of people with HCV infection had been tested and approximately a quarter of diagnosed people were treated.⁴

The global response and opportunities for elimination of HCV infection have been transformed by advances in treatment and diagnostics, as well as by price reductions.³ These advances include the introduction of curative, short-course direct-acting antiviral (DAA) therapy in 2014, and the widespread availability of rapid diagnostic testing for HCV antibody and availability of nucleic acid testing or core antigen testing for HCV viraemia. The development of evidence-based WHO guidelines for a simplified public health approach for HCV testing and treatment, and recommendations for a treat-all approach

regardless of stage of disease using a few pangenotypic regimens, has provided further support for the scale-up of testing and treatment.⁵⁻⁷ However, until recently, data have been scarce and little attention has been paid to the optimal approaches to service delivery of HCV testing, care, and treatment in different settings and populations. Much of the evidence to inform simplified approaches, such as decentralisation of care to primary-care facilities and task-shifting to nurses and non-specialists, is based on the HIV literature,⁸ in which adoption of these approaches had a transformative impact on the scale-up of antiretroviral treatment.⁹ There are even greater opportunities with HCV infection compared with HIV, because care and short-course curative treatment requires minimal expertise and monitoring.

Although previous reviews of interventions to promote uptake of HCV testing and treatment have been done, to our knowledge none have comprehensively addressed the effects of decentralisation of testing and treatment beyond tertiary-level or specialist facilities to the primary-care or secondary-care level, or task-shifting of care to non-specialists, and previous reviews have not included studies from LMICs.¹⁰⁻¹⁷ We did a systematic

review and meta-analysis of published literature, grey literature, and unpublished sources to synthesise evidence on the effectiveness of these service delivery approaches. The specific interventions considered were full decentralisation of testing and treatment at the same site or partial decentralisation of testing but referral elsewhere for treatment, integration of HCV testing and treatment with harm-reduction and other services, and task-shifting of care and treatment to non-specialists. We evaluated the effects of these interventions on six key outcomes across the HCV care cascade: uptake of serological testing, uptake of viral load testing, linkage to care, treatment uptake, uptake of cure assessment, and attainment of treatment cure. These outcomes were evaluated in four populations most affected by HCV infection: people who inject drugs, people in prisons, and people living with HIV, as well as the general population.

Methods

Search strategy and selection criteria


We did a systematic review and meta-analysis in accordance with PRISMA guidelines. We did a comprehensive search of PubMed, Embase, and WHO Global Index Medicus for studies reporting models of HCV care. The search was done on Feb 20, 2018, and included studies in all languages published from Jan 1, 2008. A further updated search was done on April 1, 2020, to identify studies published from Feb 21, 2018, to Feb 28, 2020. Searches were tailored to the functionality of each database, but generally used the following terms: “hepatitis C OR HCV” AND “delivery of health care” OR “delivery of health care, integrated” OR “model of care” OR “community care” OR “primary care”. In addition, accepted conference abstracts from the World Hepatitis Summit (2017), the International Network on Hepatitis in Substance Users (2015–18), the European Association for the Study of the Liver (2015–18), the American Association for the Study of Liver Diseases (2015–18), and the Asian Pacific Association for the Study of the Liver (2015–18) were searched. The reference lists of all retrieved articles, as well as review articles identified during the initial search, were screened for relevant citations. Forward citation checks were done to identify any additional studies. Full details of the search strategy are provided in the appendix (p 1). A secondary search on Google search engine and the WHO International Clinical Trials Registry was done to identify existing grey literature (appendix p 1). The contacts directory of the WHO Global Hepatitis Programme was also used to solicit additional studies of hepatitis service delivery from LMICs.

Authors EO and AT did the search and independently evaluated retrieved articles, abstracts, and grey literature to determine the eligibility of the study according to the inclusion criteria. PE reviewed final selection and arbitrated when there were differences between the two primary reviewers. Citations generated by electronic

scanning were assessed for relevance based on title, abstracts, and descriptor terms. We included randomised controlled trials (RCTs), non-randomised studies, and observational studies that reported interventions along the early phase of the care continuum, including serological testing, confirmatory viral load testing, and linkage to care, and the late phase of the care continuum, including treatment uptake, assessment of cure (sustained virological response at 12 weeks after completion of treatment [SVR12]), and cure rate (SVR12) for chronic HCV infection in adults (≥ 18 years). If necessary, data obtained from abstracts or grey literature were returned to authors for verification or provision of additional information. Studies with a sample size of ten or less for the largest denominator were excluded.

Data analysis

Data were extracted from eligible studies and entered into preformatted spreadsheets. The following data points were extracted: study design, participant population,



See Online for appendix

Figure 1: Study selection

AASLD=American Association for the Study of Liver Diseases. APASL=Asian Pacific Association for the Study of the Liver. EASL=European Association for the Study of the Liver. INHSU=International Network on Hepatitis in Substance Users.

location or setting of testing and treatment, the role of the health providers, and the scope of care provided. If testing was reported, additional interventions used to promote testing uptake, access to confirmatory viral load testing, and linkage to care were recorded. If treatment was reported, we documented methods of staging of liver disease, and treatment regimens used. For consistency, testing uptake was recorded as the proportion of participants tested relative to all those offered testing, whereas treatment uptake was based only on participants who had undergone viral load testing, initial staging, and treatment assessment. If a single study contained comparator groups, data from both groups were recorded in the relevant intervention category (eg, full, partial, or no decentralisation). The main outcomes of interest were HCV serological and viral load testing, linkage to care, treatment, cure assessment, and SVR12.

Studies were classified according to levels of decentralisation for testing and treatment. Full decentralisation was defined as when both testing and treatment occurred

at a primary health clinic or district hospital, harm-reduction site, or prison; partial decentralisation was defined as when testing occurred at a primary level facility followed by referral elsewhere for treatment; and no decentralisation was defined as when testing and treatment occurred at tertiary or specialist sites only. For studies of people who inject drugs, people in prisons, and people living with HIV, integration was defined as when HCV testing and treatment were done at harm-reduction sites, in prisons, or at HIV clinics alongside delivery of other key harm-reduction interventions, such as opiate substitution therapy (OST) or a needle-syringe exchange programme (NSP), or HIV care. Task-shifting was defined as delivery of HCV care and treatment by non-specialist physicians or nurses rather than specialists (eg, hepatologists). Among people who inject drugs, we categorised care facilities into three main groups: traditional OST facilities (often referred to as methadone maintenance therapy programmes or medication-assisted therapy programmes); NSP facilities

	Total (142 studies)	People who inject drugs (80 studies, 56%)	General population (37 studies, 26%)	People in prisons (20 studies, 14%)	People living with HIV (5 studies, 4%)
Low-income and middle-income countries	20 (14%)	7 (9%)	10 (27%)	1 (5%)	2 (40%)
Coverage of outcomes in care cascade					
Early phase of cascade (testing with or without linkage)	17 (12%)	8 (10%)	2 (5%)	7 (35%)	0
Late phase of cascade (treatment with or without linkage)	87 (61%)	53 (66%)	24 (65%)	8 (40%)	2 (40%)
Full cascade	38 (27%)	19 (24%)	11 (30%)	5 (25%)	3 (60%)
Decentralisation*					
Number of decentralisation study groups	154	86	41	20	7
Full decentralisation (and integration)†	88 (57%)	55 (63%)	16 (39%)	12 (60%)	5 (71%)
Partial decentralisation (testing at site, referral for care)	44 (29%)	25 (29%)	11 (27%)	8 (40%)	0
No decentralisation	22 (14%)	6 (7%)	14 (34%)	0	2 (29%)
Task-shifting*					
Number of task-shifting study groups	153	82	44	20	6
Non-specialist treatment	46 (30%)	27 (33%)	10 (23%)	6 (30%)	3 (50%)
Non-specialist treatment with onsite or telehealth-guided specialist support	24 (16%)	15 (18%)	4 (9%)	4 (20%)	1 (17%)
Specialist treatment	51 (33%)	20 (24%)	25 (57%)	3 (15%)	2 (33%)
Unknown or not applicable	32 (21%)	20 (24%)	5 (11%)	7 (35%)	0
Treatment regimen					
DAA	83 (58%)	50 (63%)	19 (51%)	10 (50%)	4 (80%)
DAA with interferon-based regimen	7 (5%)	4 (5%)	3 (8%)	0	0
Interferon-based regimen	35 (25%)	18 (23%)	13 (35%)	3 (15%)	1 (20%)
Not applicable	17 (12%)	8 (10%)	2 (5%)	7 (35%)	0
Study design					
Randomised controlled trial	6 (4%)	6 (8%)	0	0	0
Non-randomised trials	2 (1%)	1 (1%)	1 (3%)	0	0
Comparative prospective or retrospective study	11 (8%)	2 (3%)	6 (16%)	1 (5%)	2 (40%)
Non-comparative observational study	123 (87%)	71 (89%)	30 (81%)	19 (95%)	3 (60%)

Data are number of study groups, number of studies (%) or number of study groups (%). One study was stratified by people who inject drugs and people in prison, so it was included in this table twice. DAA=direct-acting antiviral. *Studies that had comparator groups with different levels of decentralisation or task-shifting were included in multiple categories. †Includes ten studies that use an embedded specialist clinic with care provided by visiting specialists.

Table 1: Summary of characteristics of 142 included studies




Figure 2: Geographical distribution of the 142 included studies
Countries in which studies were done are shaded red.

(including drop-in centres and safe injection facilities); and primary-care clinics.

Authors EO and AT assessed the risk of bias for RCTs, non-randomised studies, and observational studies using the modified Downs and Black criteria.¹⁸ Outcomes were assessed for reporting bias, selection bias, internal validity bias, and external validity bias. For study quality, the STROBE guidelines for reporting of observational studies and conference abstracts were used.¹⁹

When interventions were sufficiently similar across different studies, binomial outcomes for effect sizes were pooled and summarised with 95% CIs, adjusted using the Wald method.²⁰ Summary statistics, illustrated as forest plots for outcomes of interest, were calculated using meta-analytic methods stratified by population type, using the Freeman-Tukey correction method, and with random-effects models using the DerSimonian and Laird approach (fixed-effect models were used if heterogeneity was <20%).²¹ Heterogeneity was assessed using the I^2 statistic,²¹ and publication bias assessed using Begg's test.²² Meta-regression was used to assess the effect of decentralisation on double arcsin-transformed outcome measures, as well as the effects of selected independent variables.²³ We also pooled results from the subset of studies with a comparator group, including both randomised trials and non-randomised studies, and compared these with results from pooled analysis of non-comparator studies. *p* values obtained for comparative studies were from pairwise meta-analyses, whereas a two-sample *z*-test was used for non-comparative studies. Additional analyses were done to examine the effect of different types of harm-reduction service (NSP, OST, and other) on outcomes in studies of people who inject drugs; and the effect of the specific service provider

(nurse, general practitioner [primary-care doctor], or specialist) on SVR12 in studies of task-shifting. Analyses were done using R version 3.6.1 and Stata version 15.1.


Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

Our search identified 8050 reports, of which 5456 remained after removing duplicates (figure 1). After screening of abstracts, 5283 studies were excluded. The remaining 173 studies were reviewed and assessed for eligibility, of which 41 did not meet the eligibility criteria and were excluded. An additional ten studies were identified from reference citations and grey literature. 142 studies were included in the final synthesis, including one report with data on both people in prisons and people who inject drugs, which was counted as two separate studies. These studies included a total of 489 996 patients (239 446 [49%] from LMICs). Two additional papers identified by the updated search were not included because they did not provide any information that would have contradicted our findings on decentralisation, integration, and task-shifting.

Study characteristics are summarised in table 1 and the appendix (pp 2–25). 80 (56%) of 142 studies were focused on people who inject drugs, 20 (14%) on people in prisons, five (4%) on people living with HIV, and 37 (26%) on the general population. Figure 2 shows the geographical distribution of the included studies, of which 123 (87%) were from high-income countries, with the largest numbers from the USA (41 studies, 29%), Australia



(Figure 3 continues on next page)




Figure 3: Effect of decentralisation and integration on linkage to care for people who inject drugs, people in prisons, and the general population. Study details are provided in the appendix (pp 2–25). RCT=randomised controlled trial. MDT=multidisciplinary team.


(27, 19%), the UK (18, 13%), and Canada (17, 12%). 20 (14%) studies were from LMICs, and included seven studies in people who inject drugs (Turkey, India, China, Kenya, Georgia, Romania, and Iran), one study in people in prisons (Ukraine), two studies in people living with HIV (Myanmar and Mozambique), and ten studies in the general population (Pakistan, Egypt, Indonesia, Cameroon, Cambodia, China, and two studies each in India and Brazil). In the 37 studies in the general population (across all income settings), care was provided in primary-care settings in ten studies and in hospital-based clinics in 27 studies. Most studies in people who inject drugs were based at harm-reduction sites offering OST (48 studies), with another 14 studies in NSPs and 18 studies in other locations, such as clinics for homeless people or drop-in centres.

39 (27%) studies had a low risk of bias (score ≥ 20), 38 (27%) studies had a moderate risk (score 15–19), 49 (35%) studies had a serious risk of bias (score 10–14), and 16 (11%) had a critically high risk of bias (score <10 ; appendix p 26). The overall risk of bias was rated as moderate. Among analyses with at least ten studies, evidence of publication bias was only found for higher SVR12 rate among interferon-based regimen studies ($p=0.012$; appendix p 27).

In studies using DAAs, outcomes across the care cascade (linkage to care, treatment uptake, and SVR12) according to different levels of decentralisation among people who inject drugs, people in prisons, and the general population are presented in figure 3, figure 4, and the appendix (pp 28–40; data for studies using interferon-based

regimens are presented in the appendix pp 28–38). Heterogeneity across studies in each analysis (grouped either by decentralisation or task-shifting) was generally very high. Heterogeneity of outcomes was particularly high for serological testing uptake ($I^2>95\%$), and therefore we did not report further on this outcome in the main results, and also for treatment uptake and SVR12 for interferon-based regimens. There were insufficient studies among people living with HIV for a robust examination of outcomes according to levels of decentralisation (appendix pp 41–42). Coefficients (and 95% CIs) of meta-regressions analysing differences according to levels of decentralisation for each outcome by population group are provided in the appendix (pp 49–51; analyses according to the presence or absence of task-shifting are on p 52).

Among people who inject drugs, full decentralisation of HCV testing and treatment (and when also integrated with delivery of harm reduction services [OST, NSP, or both]) showed some evidence of being associated with both increased linkage to care (full decentralisation 72% of patients linked to care [95% CI 57–85] vs partial decentralisation 53% [38–67] vs no decentralisation 47% [11–84]; figure 3A) and increased DAA treatment uptake (full decentralisation 73% [65–80] vs partial decentralisation 66% [55–77] vs no decentralisation 35% [23–48]; figure 4A), although with overlapping CIs. Based on an examination of both the estimates and CIs from the meta-analyses and the meta-regression analyses (appendix p 51), the evidence was strongest for higher levels of treatment uptake with full decentralisation versus none. There was increased nucleic acid testing



(Figure 4 continues on next page)

uptake and linkage to care with full decentralisation versus partial or none, at harm-reduction sites providing OST or NSP, but this was statistically significant only at OST sites (appendix p 48).

Among people in prisons, there was also some evidence of increased linkage to care (full decentralisation 94% of patients linked to care [95% CI 79–100] vs partial 50% [29–71]; figure 3B) and increased treatment uptake (full decentralisation 72% of patients started DAA treatment [48–91] vs partial 39% [17–63]; figure 4B) with fully decentralised testing and treatment at the same site within a prison, compared with partial decentralisation, in which individuals were referred elsewhere for

treatment after testing, although with overlapping CIs. Based on an examination of both the estimates and CIs from the meta-analyses and the meta-regression analyses (appendix p 51), there was strong evidence for increased linkage to care with full versus partial decentralisation among people in prisons.

Among the general population, the outcomes were heterogeneous, with little evidence of differences in linkage to care or DAA treatment uptake according to level of decentralisation (figures 3C, 4C). Similarly, in the meta-regression analyses (appendix p 51), we found no evidence of differences in outcomes according to level of decentralisation.




Figure 4: Effect of decentralisation and integration on direct-acting antiviral treatment uptake for people who inject drugs, people in prisons, and the general population

Study details are provided in the appendix (pp 2–25). RCT=randomised controlled trial. RS=retrospective study.

With use of DAA-based regimens, similar high SVR12 rates ($\geq 90\%$) were achieved regardless of level of decentralisation for people who inject drugs (full decentralisation 95% [95% CI 93–97] vs partial 91% [86–95] vs none 94% [91–97]; appendix p 39), people in prisons (full 98% [96–99] vs partial 100% [77–100]; appendix p 40), people living with HIV (full 95% [87–99] vs none 100% [96–100]; appendix p 41), and the general population (full 93% [90–96] vs partial 94% [88–98] vs none 96% [92–99]; appendix p 40). In the meta-regression analyses (appendix p 52), we found no differences in DAA SVR12 rates according to level of decentralisation.

Task-shifting of care and treatment to a non-specialist was associated with similar SVR12 rates to treatment delivered by specialists using DAA-based regimens

(appendix pp 43–45) in people who inject drugs (non-specialist 96% [95% CI 93–98] vs specialist 92% [88–96]), people in prisons (non-specialist 98% [96–99] vs specialist 100% [77–100]), people living with HIV (non-specialist 98% [96–99] vs specialist 100% [96–100]), and the general population (non-specialist 94% [90–97] vs specialist 94% [92–96]). Similarly, task-shifting of care and treatment was associated with similar SVR12 rates using interferon-based regimens (appendix pp 45–47). The meta-regressions for both interferon-based and DAA regimens showed no evidence of differences between specialist-led and non-specialist-led treatment (appendix p 52). The number of studies was insufficient to investigate differences between specialist and non-specialist treatment providers among people living with HIV and people in prisons.

	Linkage to care, % (95% CI)				Treatment uptake, % (95% CI)				Cure assessment, % (95% CI)			
	Full decentralisation	Partial decentralisation	No decentralisation	p value	Full decentralisation	Partial decentralisation	No decentralisation	p value	Full decentralisation	Partial decentralisation	No decentralisation	p value
People who inject drugs												
Full decentralisation vs none												
Comparative	88% (77–94)	..	67% (54–78)	0.008	88% (65–100)	..	33% (25–43)	<0.001	47% (31–64)	..	69% (44–86)	0.130
Wade et al (2018), RCT	88% (77–94)	..	67% (54–78)	..	74% (60–85)	..	39% (26–53)	..	47% (31–64)	..	69% (44–86)	..
Middleton et al (2018), RCS	98% (88–100)	..	27% (17–41)
Non-comparative	73% (56–87)	..	26% (13–44)	<0.001	71% (62–79)	..	56% (21–86)	0.381	83% (76–90)	..	100% (98–100)	<0.001
Number of studies	12	..	1	..	21	..	1	..	28	..	2	..
Full vs partial decentralisation												
Comparative	39% (35–44)	26% (22–30)	..	<0.001	72% (32–98)	83% (10–100)	..	0.954	96% (91–99)	95% (87–98)	..	0.697
Radley et al (2018), RCT	39% (35–44)	26% (22–30)	52% (45–59)	44% (36–53)	96% (91–99)	95% (87–98)
Alavi et al (2018), PCS	88% (77–95)	100% (91–100)
Cooper et al (2017), RCS
McClure et al (2017), PCS
Non-comparative	73% (56–87)	55% (39–70)	..	0.108	71% (62–79)	64% (53–74)	..	0.310	83% (76–90)	85% (73–94)	..	0.756
Number of studies	12	15	21	10	28	4
General population												
Full vs partial decentralisation												
Comparative	63% (47–77)	52% (48–57)	..	0.146	78% (73–82)	70% (50–86)	..	0.826
Cooper et al (2017), RCS	63% (47–77)	52% (48–57)	78% (73–82)	70% (50–86)
Non-comparative	71% (62–79)	64% (53–74)	..	0.310	86% (79–92)	89% (47–100)	..	0.829
Number of studies	4	4	10	4

A full list of studies is provided in the appendix (pp 2–25). p values for comparative studies were from pairwise meta-analyses of dichotomous outcomes. p values for non-comparative studies were from two-sample z-tests comparing the results of meta-analyses for proportions using double arcsin transformations. RCT=randomised controlled trial. RCS=retrospective comparative study. PCS=prospective comparative study.

Table 2: Comparison of linkage to care, treatment uptake, and cure assessment in direct-acting antiviral regimen studies with or without comparative groups, according to population group and level of decentralisation

Of 142 studies, 13 (9%) had comparator groups (RCTs, non-randomised trials, or prospective cohort studies) and had examined the effect of decentralisation of care or task-shifting of care and treatment to non-specialists. A comparison of available outcomes from this subgroup of studies using DAA regimens across groups with different levels of decentralisation (seven studies) and task-shifting (five studies), with the corresponding results for the non-comparative studies, are shown in tables 2, 3, and 4 (outcomes of studies using interferon-based regimens are shown in the appendix pp 53–56). Findings were generally consistent between comparative and non-comparative studies. Among people who inject drugs, linkage to care and treatment uptake were considerably higher with full decentralisation compared with no

decentralisation, with smaller increases observed for full decentralisation versus partial decentralisation (table 2). For SVR12, there were no differences by level of decentralisation or task-shifting status for any population (tables 3, 4). Meta-analyses of studies with comparator groups also showed similar results for full decentralisation versus partial or no decentralisation across all outcomes to those observed from the overall meta-analysis. Meta-regression analyses for outcomes according to level of decentralisation and population were limited by the lack of comparative studies, with only one study available for many of the comparisons (appendix pp 53–56). Results of the meta-regression analyses of study variables on the outcomes are presented and described in the appendix (p 49).

In addition to levels of decentralisation and task-shifting, other interventions were used in the various studies to promote uptake of testing. However, the use of multiple combinations of different strategies and outcomes precluded a formal quantitative analysis of their independent contribution, or attribution of an outcome to a particular intervention. We identified 11 (8%) studies that achieved high levels of coverage (>75%) for at least three steps across the care cascade (testing uptake, nucleic acid testing uptake, linkage to care, treatment uptake, and cure assessment).^{24–32} These studies included two in the general population;^{24,25} one in people in prisons (full decentralisation);²⁶ two in people living with HIV (Nguyen A, Médecins Sans Frontières, personal communication); and six in people who inject drugs (full decentralisation^{27–31} and partial decentralisation³²). Across these studies, common strategies were adopted that have previously been shown to promote testing (use of rapid diagnostic tests, laboratory-based enzyme immunoassay,^{28,29,32} villager or peer workers,²⁴ and use of dried blood spot testing³³); uptake of nucleic acid testing (reflex laboratory nucleic acid testing,^{27,28} immediate sample collection following positive rapid diagnostic test,^{24,25} or use of point-of-care viral load assays); linkage to care (use of village promoters or peer workers and provision of sample transport);²⁴ and treatment uptake (free treatment,²⁴ peer workers,²⁴ and non-specialists^{25,27,29,31}).

Discussion

To our knowledge, this global systematic review is the most comprehensive review of service delivery models for HCV care to date. It was based on 142 studies from 34 countries, of which around a sixth were LMICs. It encompassed studies in four main affected populations: people who inject drugs, people in prisons, people living with HIV, and the general population, and examined the effects of different levels of decentralisation and task-shifting on all six key outcomes across the cascade of care.

This study has three key findings. First, we found that full decentralisation and integration of HCV testing and treatment at sites providing harm-reduction services (OST, NSP, or both, and also mental health support) for people who inject drugs and on site for people in prisons was associated with increased linkage to care and treatment. The strongest evidence was for improved treatment uptake with full decentralisation and integrated care among people who inject drugs, and for linkage to care with full decentralisation and integrated care among people in prisons. Second, similarly high rates of HCV cure (SVR12) were found in a wide range of decentralised settings for care and treatment, including harm-reduction sites, prisons, and primary-care or community settings, to those found when care was delivered in tertiary-level facilities. Third, task-shifting to non-specialist primary-care physicians or nurses was associated with similarly high levels of

	Full decentralisation, % (95% CI)	Partial decentralisation, % (95% CI)	No decentralisation, % (95% CI)	p value
People who inject drugs				
Full decentralisation vs none				
Comparative	100% (78–100)	..	100% (72–100)	0.688
Wade et al (2018), RCT	100% (78–100)	..	100% (72–100)	..
Middleton et al (2018), RCS
Non-comparative	95% (93–97)	..	94% (90–97)	0.627
Number of studies	28	..	3	..
Full vs partial decentralisation				
Comparative	91% (84–95)	93% (90–95)	..	0.422
Radley et al (2018), RCT
Alavi et al (2018), PCS
Cooper et al (2017), RCS
McClure et al (2017), PCS	Nurse 88% (78–95); GP 93% (82–99)	93% (90–95)
Non-comparative	95% (93–97)	90% (83–96)	..	0.150
Number of studies	28	6
General population				
Full vs partial decentralisation				
Comparative	95% (74–100)	95% (91–97)	..	0.780
Cooper et al (2017), RCS	95% (74–100)	95% (91–97)
Non-comparative	93% (90–96)	93% (86–98)	..	1.000
Number of studies	10	4
People living with HIV				
Full decentralisation vs none				
Comparative	94% (88–99)	..	100% (93–100)	0.867
Doyle et al (2018), NRS	94% (88–99)	..	100% (93–100)	..
Non-comparative	99% (97–100)	..	NA	NA
Number of studies	3	..	0	..

A full list of studies is provided in the appendix (pp 2–25). p values for comparative studies were from pairwise meta-analyses of dichotomous outcomes. p values for non-comparative studies were from two-sample z-tests comparing the results of meta-analyses for proportions using double arcsin transformations. SVR12=sustained virological response at 12 weeks after completion of treatment. GP=general practitioner. RCT=randomised controlled trial. RCS=retrospective comparative study. PCS=prospective comparative study. NRS=non-randomised study. NA=not applicable (tests could not be performed due to a paucity of data).

Table 3: Comparison of SVR12 outcomes in direct-acting antiviral regimen studies with or without comparative groups, according to population group and level of decentralisation

HCV cure using DAA regimens to those achieved by specialist-delivered care in all populations studied. Similar findings were also observed in studies using the older interferon-based regimens, as opposed to DAA regimens.

Our findings are consistent with those from the HIV literature, which show similar rates of viral suppression on antiretroviral therapy (ART), as well as increased uptake of testing and treatment, with full decentralisation (ie, community-based HIV testing and treatment at lower-level health facilities) compared with no decentralisation^{15,33–35} and also with care delivered by non-specialists, including nurses, compared with care delivered by specialists.^{36–38} In our study, the effects of decentralisation were most notable among people who inject drugs and

	Non-specialist care, % (95% CI)	Specialist care, % (95% CI)	p value
People who inject drugs			
Comparative	93% (86–98)	95% (92–97)	0.460
Wade et al (2018), RCT	PCPs or nurses 100% (76–100)	100% (74–100)	..
McClure et al (2017), PCS	Nurses 88% (78–95); GPs 93% (82–99)	93% (90–95)	..
Non-comparative	96% (94–98)	92% (86–96)	0.145
Number of studies	22	8	..
General population			
Comparative	95% (92–98)	94% (91–96)	0.466
Cooper et al (2017), RCS	Nurses 95% (74–100)	95% (91–97)	..
Kattakuzhy et al (2017), NRS	PCPs 95% (90–98); nurses 95% (90–98)	92% (89–95)	..
Non-comparative	93% (87–97)	94% (91–97)	0.737
Number of studies	5	9	..
People living with HIV			
Comparative	94% (88–98)	100% (93–100)	0.065
Doyle et al (2018), NRS	Nurses 94% (88–98)	100% (93–100)	..
Non-comparative	99% (97–100)	NA	NA
Number of studies	3	0	..

A full list of studies is provided in the appendix (pp 2–25). p values for comparative studies were from pairwise meta-analyses of dichotomous outcomes. p values for non-comparative studies were from two-sample z-tests comparing the results of meta-analyses for proportions using double arcsin transformations. SVR12=sustained virological response at 12 weeks after completion of treatment. RCT=randomised controlled trial. PCP=primary care physician. PCS=prospective comparative study. GP=general practitioner. RCS=retrospective comparative study. NRS=non-randomised study. NA=not applicable (tests could not be performed due to a paucity of data).

Table 4: Comparison of SVR12 outcomes in direct-acting antiviral regimen studies with or without comparative groups, according to population group and task-shifting status

those in prisons. People who inject drugs, in particular, have difficulties accessing health services, including getting tested, linking to care, and navigating tertiary-care services.³⁹ Similar to our systematic review, previous studies of ART have shown positive effects of the provision of integrated HIV care for people who inject drugs, with on-site community HIV testing and ART treatment.^{40–42} For HIV, the convenient co-location of testing and treatment integrated within OST services or primary care or community sites, where multiple needs can be met in one accessible setting, has been an important facilitator of access to care for people who inject drugs.^{8,41–43} WHO currently recommends offering HIV care and ART at OST sites.^{8,42} Our study findings regarding HCV support similar integration of HCV testing and treatment, and also provide new evidence that integration and co-location of HCV care and treatment can be effective not only at OST sites, but also at NSP sites.

There was considerable heterogeneity in outcomes (especially for testing uptake) across populations, care settings, treatment regimen, and service delivery interventions. However, SVR12 results for DAAs were consistently high (>90%) across all populations, care settings (eg, OST or NSP sites, prisons, primary-care clinics), and types of care provider (eg, nurses, general practitioners, addiction specialists, hepatologists), as well as across different levels of decentralised and integrated

care. These findings are consistent with reports of successful treatment outcomes among people who inject drugs, including those with recent drug use and those receiving OST.⁴⁴ We found the strongest evidence for full decentralisation was among people who inject drugs and people in prisons, but differences by level of decentralisation to primary care were not observed among studies in the general population, for which results were highly heterogeneous. This discrepancy is probably due to the currently more well established models for delivery of HCV care in OST and NSP sites in high-income countries as compared with the diverse care models for delivery of HCV care in primary-care settings for the general population.

Key strengths of this systematic review were the large number of studies included, of which around a sixth were from LMICs, and the inclusion of additional studies through searches of conference presentations and grey literature. Our updated search from 2018 to 2020 yielded only two potentially eligible studies that were not included. We also did a comprehensive analysis of the effects of interventions across all six outcomes along the cascade of HCV care. The inclusion of single-arm observational studies alongside comparative studies considerably expanded the evidence base from LMICs, and it also enabled an additional comparison of findings between studies with comparator groups and non-comparative studies. A high proportion of our studies were based on DAAs, reflecting current treatment practice.

There were several limitations to this systematic review. First, the meta-analysis was based largely on single-arm observational studies. Few studies (13, 9%) had a comparator group enabling a direct comparison of different levels of decentralisation or task-shifting, and of these only four were RCTs (there were six RCTs in total). This may introduce considerable selection bias and result in an overestimate of the effects of the interventions. Second, studies from LMICs were still under-represented, and there was a relative paucity of data on the early testing and linkage part of the cascade compared with the later treatment steps in the cascade. In addition, the use of terminology such as decentralisation, decentralised care, or task-shifting is still infrequent in the HCV literature, and it is possible that, as a result, some relevant studies were overlooked in our search strategy. Third, many included studies used several interventions targeting different steps in the care cascade, such as strategies to promote uptake and rate of serological testing (eg, opt-out testing, peer and outreach workers, electronic medical record and clinician reminders, and rapid diagnostic tests), HCV RNA confirmation (eg, reflex laboratory testing, immediate sample collection, or point-of-care viral load instruments such as GeneXpert), and linkage to care (eg, use of peer workers or patient navigators). Of note, ten studies that reported consistently high levels of coverage (>75%) across the care cascade had, in addition

to full decentralisation, adopted several other well established interventions to promote access to testing and treatment. The use of multiple combinations of different strategies and outcomes precluded a formal quantitative analysis of their independent contributions, and we were unable to attribute an outcome to a particular intervention. Fourth, financial or socioeconomic factors were not reported that might have adversely affected engagement and impact on specific outcomes such as linkage rate and treatment uptake, especially in people who inject drugs or people in prisons, as well as people who are homeless.

This systematic review highlights the need for more methodologically rigorous comparative studies on packages of different interventions to promote the uptake of HCV testing, and linkage to assessment and treatment uptake, especially in LMICs. We identified few studies of different models of fully decentralised HCV testing, care, and treatment among the general population in primary care, but evidence from ongoing studies is likely to be available over the next 2 years, when an updated review would be helpful. Future studies should provide a full description of the service delivery model, and evaluation should capture effectiveness of interventions across the entire continuum of care and not just the treatment-related outcomes. Including costs would allow for comparative cost-effectiveness analyses. Additional and new strategies to promote testing and treatment access in LMICs that are currently being evaluated include the strategic use of point-of-care multi-platform technologies for measurement of HCV viral load such as GeneXpert, electronic medical record prompts,^{45,46} use of mobile outreach services, especially in homeless populations,^{47–49} pharmacy-led testing and treatment initiation,^{50,51} and telementoring to support non-specialists.^{52,53}

This systematic review has several major policy and clinical management implications for the scale-up of testing and treatment that is needed to achieve global HCV elimination targets. The WHO 2017 testing guidelines already recommend the adoption of several strategies to enhance uptake of hepatitis testing and linkage to care, including peer workers, clinician reminders for testing, and provision of testing as part of integrated services, based on a 2016 systematic review.^{5,17} Similarly, the WHO 2018 guidelines for HCV infection promoted eight good-practice principles for simplified service delivery, including decentralisation, integration, and task-shifting.⁷ Our systematic review now provides a robust evidence base to support global policy and national guidelines for expanding HCV services beyond tertiary or specialist facilities to fully decentralised, co-located HCV testing and treatment at the primary-care and secondary-care level, harm-reduction services, prisons, and HIV clinics. We also show evidence for the effectiveness of task-shifting of HCV care and treatment to primary-care physicians and nurses, which should be supported by training and mentorship.⁶ Compared with HIV, there are even greater opportunities for

decentralisation and task-shifting of HCV care and treatment because of the simplicity of short-course, curative, pangenotypic DAA regimens with minimal side-effects. A 2018 systematic review showed favourable SVR12 cure rates among people receiving OST and those with recent drug use.⁵⁴ Of note, our study shows the feasibility of improving access to diagnosis and treatment among people who inject drugs and people in prisons, who are some of the most difficult populations to reach, which is critical to achieve elimination targets and reduce prevalence and ongoing transmission of HCV.

Contributors

PE conceived the study proposal, developed the overall methods and approach for the systematic review and meta-analysis, and oversaw the project. EO did the literature search. EO and AT extracted data. EO and AT independently assessed the quality of each record using a quality assessment tool. AT, RS, and SK did the analyses and generated all forest plots, which were reviewed by EO and PE. EO and PE led the writing of the manuscript, and PE with AT made all subsequent revisions to the manuscript. All authors commented and contributed text, and approved the final manuscript. EO and PE had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

Declaration of interests

We declare no competing interests.

Data sharing

The full search strategy and results used to generate data that inform the conclusion of this systematic review can be found in the appendix.

Acknowledgments

This project was funded through an enabler grant to the WHO Global Hepatitis Programme from Unitaid. WHO experts were involved in the technical and scientific discussions of this project. The writing of this paper was done solely by the authors. The authors are grateful to a number of individuals who provided valuable input to the project and on the manuscript, including Marc Bulterys, Niklas Luhmann, Christian Ramers, Nathan Ford, and Annette Verster.

Editorial note: the *Lancet* Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

References

- 1 WHO. Global hepatitis report, 2017. April, 2017. <https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en> (accessed Jan 11, 2021).
- 2 WHO. Global health sector strategy on viral hepatitis 2016–2021. June, 2016. <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en> (accessed Jan 11, 2021).
- 3 WHO. Global report on access to hepatitis C treatment: focus on overcoming barriers. October, 2016. <https://apps.who.int/iris/handle/10665/250625> (accessed Jan 11, 2021).
- 4 WHO. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. July, 2019. <https://www.who.int/hiv/strategy2016-2021/progress-report-2019/en> (accessed Jan 11, 2021).
- 5 Easterbrook PJ, WHO Guidelines Development Group. Who to test and how to test for chronic hepatitis C infection—2016 WHO testing guidance for low- and middle-income countries. *J Hepatol* 2016; **65** (suppl): S46–66.
- 6 WHO. Guidelines on hepatitis B and C testing. February, 2017. <https://www.who.int/hepatitis/publications/guidelines-hepatitis-b-testing/en> (accessed Jan 11, 2021).
- 7 WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July, 2018. <https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en> (accessed Jan 11, 2021).
- 8 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach—second edition. June, 2016. <https://www.who.int/hiv/pub/arv/arv-2016/en> (accessed Jan 11, 2021).

- 9 Bemelmans M, van den Akker T, Ford N, et al. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. *Trop Med Int Health* 2010; **15**: 1413–20.
- 10 Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. *Int J Drug Policy* 2017; **47**: 34–46.
- 11 Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis MA. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review. *Eur J Public Health* 2014; **24**: 781–88.
- 12 Lazarus JV, Sperle I, Maticic M, Wiessing L. A systematic review of hepatitis C virus treatment uptake among people who inject drugs in the European region. *BMC Infect Dis* 2014; **14** (suppl 6): S16.
- 13 Mathes T, Antoine SL, Pieper D. Factors influencing adherence in hepatitis-C infected patients: a systematic review. *BMC Infect Dis* 2014; **14**: 203.
- 14 McDermott CL, Lockhart CM, Devine B. Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. *J Virus Erad* 2018; **4**: 118–22.
- 15 Tucker JD, Tso LS, Hall B, et al. Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention. *EBioMedicine* 2017; **17**: 163–71.
- 16 Wade AJ, Veronese V, Hellard ME, Doyle JS. A systematic review of community based hepatitis C treatment. *BMC Infect Dis* 2016; **16**: 202.
- 17 Zhou K, Fitzpatrick T, Walsh N, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. *Lancet Infect Dis* 2016; **16**: 1409–22.
- 18 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* 1998; **52**: 377–84.
- 19 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J Surg* 2014; **12**: 1495–99.
- 20 Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. *Am Stat* 1998; **52**: 119–26.
- 21 Higgins JPT, Green S (eds). *Cochrane handbook for systematic reviews of interventions*, version 5.0.0. London: The Cochrane Collaboration, 2008.
- 22 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; **50**: 1088–101.
- 23 Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med* 2003; **22**: 2693–710.
- 24 Shiha G, Metwally AM, Soliman R, Elbasiony M, Mikhail NNH, Easterbrook P. An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project. *Lancet Gastroenterol Hepatol* 2018; **3**: 778–89.
- 25 Ford MM, Jordan AE, Johnson N, et al. Check Hep C: a community-based approach to hepatitis C diagnosis and linkage to care in high-risk populations. *J Public Health Manag Pract* 2018; **24**: 41–48.
- 26 Cuadrado A, Llerena S, Cobo C, et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. *Am J Gastroenterol* 2018; **113**: 1639–48.
- 27 Hashim A, O’Sullivan M, Williams H, Verma S. Developing a community HCV service: project ITTREAT (integrated community-based test–stage–TREAT) service for people who inject drugs. *Prim Health Care Res Dev* 2018; **19**: 110–20.
- 28 Lindenburg CEA, Lambers FAE, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. *Eur J Gastroenterol Hepatol* 2011; **23**: 23–31.
- 29 Jack K, Willott S, Mannes J, Varnam MA, Thomson BJ. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. *Aliment Pharmacol Ther* 2009; **29**: 38–45.
- 30 Gilliver R, Chronister K, Lothian R, Kearley J, Read P. Daily dosing of direct acting antivirals from a public opioid substitution therapy (OST) program for marginalised clients in Kings Cross, Sydney. 7th International Symposium on Hepatitis Care in Substance Users; Cascais, Portugal; Sept 19–21, 2018 (abstr A103).
- 31 Olaizola C, Maitre C, Bidart E, et al. Test and treat: 6 years of HCV rapid testing among drug users in the Bayonne area (France). 7th International Symposium on Hepatitis Care in Substance Users; Cascais, Portugal; Sept 19–21, 2018 (abstr).
- 32 Sander-Hess C, Parker M, Maggs J, Hansford L. INTACCT: integrated community hepatitis C treatment. 7th International Symposium on Hepatitis Care in Substance Users; Cascais, Portugal; Sept 19–21, 2018 (abstr).
- 33 Kredt T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and middle-income countries. *Cochrane Database Syst Rev* 2013; **6**: CD009987.
- 34 Mavegam BO, Pharr JR, Cruz P, Ezeanolue EE. Effective interventions to improve young adults’ linkage to HIV care in sub-Saharan Africa: a systematic review. *AIDS Care* 2017; **29**: 1198–204.
- 35 Sharma M, Ying R, Tarr G, Barnabas R. Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan Africa. *Nature* 2015; **528**: S77–85.
- 36 Fairall L, Bachmann MO, Lombard C, et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. *Lancet* 2012; **380**: 889–98.
- 37 Seidman G, Atun R. Does task shifting yield cost savings and improve efficiency for health systems? A systematic review of evidence from low-income and middle-income countries. *Hum Resour Health* 2017; **15**: 29.
- 38 Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. *Hum Resour Health* 2010; **8**: 8.
- 39 Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. *Clin Infect Dis* 2013; **57** (suppl 2): S62–69.
- 40 Simeone C, Shapiro B, Lum PJ. Integrated HIV care is associated with improved engagement in treatment in an urban methadone clinic. *Addict Sci Clin Pract* 2017; **12**: 19.
- 41 WHO. Consolidated guidelines on HIV testing services: 5Cs: consent, confidentiality, counselling, correct results and connection 2015. July, 2015. <https://apps.who.int/iris/handle/10665/179870> (accessed Jan 11, 2021).
- 42 WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations: 2016 update. July, 2016. <https://www.who.int/hiv/pub/guidelines/keypopulations-2016/en> (accessed Jan 11, 2021).
- 43 UN Office on Drugs and Crime, International Network of People Who Use Drugs, UNAIDS, et al. Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions. Vienna: United Nations Office on Drugs and Crime, 2017.
- 44 Grebely J, Feld JJ, Wyles D, et al. Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: an analysis of phase 3 studies. *Open Forum Infect Dis* 2018; **5**: ofy001.
- 45 Geboy AG, Nichols WL, Fernandez SJ, Desale S, Basch P, Fishbein DA. Leveraging the electronic health record to eliminate hepatitis C: screening in a large integrated healthcare system. *PLoS One* 2019; **14**: e0216459.
- 46 Thuluvath PJ, Feldman H, Horowitz A, Lowe G. Screening for hepatitis C in baby boomer population using EMR pop-up and targeted mailing from primary care physicians in a single community teaching hospital. *Hepatology* 2016; **64** (suppl 1): 833.
- 47 Lambert JS, Murtagh R, Menezes D, et al. ‘HepCheck Dublin’: an intensified hepatitis C screening programme in a homeless population demonstrates the need for alternative models of care. *BMC Infect Dis* 2019; **19**: 128.
- 48 Remy AJ, Bouchkira H, Lamarre P, Montabone S. Hepatitis Mobile Team: a new concept for benefit toward drugs users and precarious people with hepatitis C in France. *Hepatology* 2016; **64** (suppl 1): 775.

- 49 Surey J, Story A, Menezes D, Conneely J, Hayward A. EARTH Study (phase 1): expanding access to rapid treatment for hepatitis C. *J Hepatol* 2016; **64** (suppl): S461–62.
- 50 David C, David D, Essex W, Deming P, Qualls CR, Mera J. Hepatitis C treatment outcomes in a pharmacist-managed clinic in a rural tribal health system. *Hepatology* 2017; **66** (suppl 1): 609.
- 51 Radley A, Tait J, Stephens B, Dillon J. Can dried blood spot testing for hepatitis C in community pharmacy increase uptake? Interim reporting of a quasi-experimental study. 4th International Conference on Hepatitis in Substance Users; Sydney, NSW, Australia; Oct 7–9, 2015 (abstr).
- 52 Beste LA, Glorioso TJ, Ho PM, et al. Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs. *Am J Med* 2017; **130**: 432–38.e3.
- 53 Chan PP, Mohsen W, Whelan MC, et al. Project ECHO in Australia: a novel tele-mentoring service to aid hepatitis C treatment in difficult to access populations. *Hepatology* 2017; **66** (suppl 1): 581.
- 54 Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2018; **3**: 754–67.